TY - JOUR T1 - Association of olfactory dysfunction with hospitalization for COVID-19: a multicenter study in Kurdistan JF - medRxiv DO - 10.1101/2020.07.26.20158550 SP - 2020.07.26.20158550 AU - Hosna Zobairy AU - Erfan Shamsoddin AU - Mohammad Aziz Rasouli AU - Nasrollah Veisi Khodlan AU - Ghobad Moradi AU - Bushra Zareie AU - Sara Teymori AU - Jalal Asadi AU - Ahmad Sofi-Mahmudi AU - Ahmad R Sedaghat Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/28/2020.07.26.20158550.abstract N2 - Objective To evaluate the association of olfactory dysfunction (OD) with hospitalization for COVID-19.Study Design Multi-center cohort study.Setting Emergency departments of thirteen COVID-19-designed hospitals in Kurdistan province, Iran.Subjects and Methods Patients presenting with flu-like symptoms who tested positive by RT-PCR for COVID-19 between May 1st and 31st, 2020. At the time of presentation and enrollment, patients were asked about the presence of OD, fever, cough, shortness of breath, headache, rhinorrhea and sore throat. The severity of OD was assessed on an 11-point scale from 0 (none) to 10 (anosmia). Patients were either hospitalized or sent home for outpatient care based on standardized criteria.Results Of 203 patients, who presented at a mean of 6 days into the COVID-19 disease course, 25 patients (12.3%) had new OD and 138 patients (68.0%) were admitted for their COVID-19. Patients admitted for COVID-19 had a higher prevalence of all symptoms assessed, including OD (p<0.05 in all cases), and OD identified admitted patients with 84.0% sensitivity and 34.3% specificity. On univariate logistic regression, hospitalization was associated with OD (odds ratio [OR] = 2.47, 95%CI: 1.085–6.911, p=0.049). However, hospitalization for COVID-19 was not associated with OD (OR=3.22, 95% CI: 0.57–18.31, p=0.188) after controlling for confounding demographics and comorbidities.Conclusion OD may be associated with hospitalization for (and therefore more severe) COVID-19. However, this association between OD and COVID-19 severity is more likely driven by patient characteristics linked to OD, such as greater numbers of COVID-19 symptoms experienced or high-risk comorbidities.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of Kurdistan University of Medical Sciences (ref. no. IR.MUK.REC.1399.006).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available upon request. ER -